{"title": "NewsRamp Curated News Feed for Health Wellness", "description": "NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.", "site_url": "https://www.newsramp.com", "display_name": "NewsRamp.com", "next_page": "https://feeds.newsramp.net/tldr/newsramp/moderated/10/2/health-wellness.json", "instructions": "Fine tune the feed as follows /tldr/category/newsramp/en/all/20/1/health-wellness.json /tldr/category/en/[all/moderated]/[records per page up to 100]/[page number]/health-wellness.json - Available Language Codes English=en", "prev_page": "", "current_page": 1, "total_records": 4634, "total_pages": 464, "image_url": "https://newsramp.com/light-logo.svg", "language": "en", "ttl": 10, "news": [{"feed_item_id": 30959, "prhash_id": "eed26ce8e40e6672ae56eb68c46ec1a1", "headline": "Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis", "content": "        <article>        <h1>Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Aclarion's new patent strengthens its competitive moat with AI-driven workflow automation, enabling scalable growth and enhanced gross margins in the chronic pain market.</li>            <li>The patent covers machine learning models that extract biomarkers from MRS data and implement automated quality controls for consistent, reproducible pain assessment outputs.</li>            <li>This technology helps physicians accurately identify painful spinal discs, potentially improving surgical outcomes and addressing chronic low back pain affecting millions globally.</li>            <li>Aclarion's AI platform analyzes magnetic resonance spectroscopy to distinguish painful from non-painful spinal discs, backed by 64 patents worldwide.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development represents a significant advancement in personalized medicine for chronic pain management, potentially affecting millions suffering from debilitating back pain. By securing patent protection for AI-driven analysis of magnetic resonance spectroscopy data, Aclarion creates a defensible technological advantage that could accelerate clinical adoption and standardization of objective pain assessment tools. For patients, this means potentially more accurate diagnoses, reduced unnecessary procedures, and improved surgical outcomes when intervention is needed. For healthcare systems, it offers a scalable solution to a pervasive problem that costs billions annually in treatment expenses and lost productivity. The technology's ability to provide reproducible, standardized outputs across different imaging systems addresses a critical barrier to widespread implementation of objective pain assessment tools in clinical practice.</p>        <h2>Summary</h2>        <p><p>Aclarion, Inc., a commercial-stage healthcare technology company trading on Nasdaq as ACON and ACONW, has secured a significant U.S. Patent (#12,601,803) that strengthens its position in the chronic low back pain market. The patent, titled 'System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain,' specifically protects the company's machine learning platform for analyzing magnetic resonance spectroscopy (MRS) data. This intellectual property advancement covers Aclarion's use of artificial intelligence in future iterations of its flagship cloud-based platform, Nociscan, which helps physicians distinguish between painful and non-painful spinal discs by converting complex MRS spectral data into clinically actionable insights.</p><p>The newly issued patent represents a strategic milestone for Aclarion, expanding its intellectual property portfolio to 64 issued and pending patents worldwide and creating what the company describes as a 'long-term competitive moat.' According to CEO Brent Ness, the patent strengthens the foundation of their platform by protecting how they leverage AI to transform complex spectroscopy data into meaningful information that physicians can integrate into everyday practice. The technology enables automated biomarker identification, accelerated report generation, and reduced manual quality reviews\u2014capabilities that will help the company scale efficiently while enhancing already strong gross margins. Importantly, the patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, ensuring consistent, reproducible outputs across different imaging systems and clinical sites.</p><p>This development matters because chronic low back pain affects approximately 266 million people worldwide, representing a significant global healthcare challenge. Aclarion's technology addresses this underserved market with evidence showing up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. The patent protection enables Aclarion to build what they call a 'differentiated, software-driven platform' that could redefine how spine conditions are assessed. For those interested in learning more about the company's developments, they can visit the Latest News section on Aclarion's website or check the company's newsroom for updates relating to $ACON. The patent itself can be reviewed through the provided link to the USPTO database, offering transparency about the protected technology that could transform pain assessment methodologies.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/eed26ce8e40e6672ae56eb68c46ec1a1.30959.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/eed26ce8e40e6672ae56eb68c46ec1a1.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://prismmediawire.com'>PRISM Mediawire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/prism/en//eed26ce8e40e6672ae56eb68c46ec1a1'>Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis.</a></p></div>        </article>    ", "published": "2026-04-16T10:48:15+00:00", "audio_release": "https://cdn.newsramp.net/audio/eed26ce8e40e6672ae56eb68c46ec1a1.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/eed26ce8e40e6672ae56eb68c46ec1a1.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-4.jpg", "site_handle": "prism", "seo_description": "Aclarion secures U.S. patent for AI platform analyzing MRI data to identify painful spinal discs, expanding IP portfolio to 64 patents for chronic low back pain diagnosis technology.", "newsramp_curated": "https://newsramp.com/curated-news/aclarion-secures-ai-patent-to-revolutionize-chronic-back-pain-diagnosis/eed26ce8e40e6672ae56eb68c46ec1a1"}, {"feed_item_id": 30952, "prhash_id": "293fa383bc5a76e31f9db978e6ed4246", "headline": "GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026", "content": "        <article>        <h1>GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>GeoVax's GEO-MVA vaccine offers a competitive advantage by addressing global supply constraints for orthopoxvirus vaccines, potentially capturing market share through expedited regulatory pathways and strategic partnerships.</li>            <li>GeoVax plans to initiate a pivotal Phase 3 immuno-bridging study for GEO-MVA in late 2026, following regulatory alignment with EMA and completion of cGMP manufacturing for clinical-grade vaccine.</li>            <li>GEO-MVA aims to improve global public health by providing a critically needed vaccine supply for mpox and smallpox, enhancing biosecurity preparedness and protecting vulnerable populations worldwide.</li>            <li>GeoVax's GEO-MVA vaccine uses Modified Vaccinia Ankara technology to target both mpox and smallpox, representing a dual-purpose solution to address recurring outbreaks and depleted government stockpiles.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because it addresses a critical gap in global vaccine supply for orthopoxviruses like mpox and smallpox, which pose ongoing public health threats. Recent outbreaks have depleted government stockpiles, highlighting vulnerabilities in pandemic preparedness. GEO-MVA's accelerated regulatory pathway could provide a much-needed domestic manufacturing alternative, reducing reliance on single foreign sources and enhancing biosecurity. For populations at risk\u2014including healthcare workers, immunocompromised individuals, and those in outbreak regions\u2014this vaccine represents a potential safeguard against future epidemics. Furthermore, successful development would strengthen global health infrastructure, offering a tool for rapid response to emerging viral strains and supporting international preparedness frameworks.</p>        <h2>Summary</h2>        <p><p>GeoVax Labs, a clinical-stage biotechnology company, has announced its 2025 financial results alongside significant progress on its lead vaccine candidate, GEO-MVA. The company's primary focus is advancing this Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, with plans to initiate a pivotal Phase 3 immuno-bridging study in the second half of 2026. This development follows regulatory alignment with the European Medicines Agency (EMA) that supports an accelerated pathway, potentially bypassing earlier trial phases. CEO David Dodd emphasized that GEO-MVA addresses critical global supply constraints for orthopoxvirus vaccines, depleted government stockpiles, and the need for diversified domestic manufacturing to enhance public health preparedness and biosecurity.</p><p>Beyond its priority program, GeoVax continues to advance a diversified pipeline including GEO-CM04S1, a next-generation COVID-19 vaccine showing promising interim results in immunocompromised populations, and Gedeptin\u00ae, an oncology therapy for head and neck cancer that has entered into an exclusive license agreement with Emory University. The company reported a net loss of $21.5 million for 2025, with decreased research expenses following the termination of a BARDA contract, and maintains a cash position of $3.1 million. For more information, visit www.geovax.com, where investors and stakeholders can find detailed corporate updates and forward-looking statements about these clinical developments.</p><p>The company's strategic positioning at the intersection of recurring mpox outbreaks, evolving viral strains, and policy-driven demand for vaccine supply diversification makes GEO-MVA potentially central to global orthopoxvirus preparedness. With manufacturing readiness established through completed cGMP production and fill-finish operations, GeoVax is actively engaging international regulatory and governmental stakeholders to align with procurement frameworks. This comprehensive approach underscores the company's commitment to addressing critical medical needs while maximizing long-term value, as detailed in their recent financial disclosures and operational highlights that signal important milestones toward potential regulatory approval and commercialization.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/293fa383bc5a76e31f9db978e6ed4246.30952.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/293fa383bc5a76e31f9db978e6ed4246.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/geovax-reports-2025-year-end-financial-results-and-provides-business-update-7086367/293fa383bc5a76e31f9db978e6ed4246'>GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026.</a></p></div>        </article>    ", "published": "2026-04-15T20:04:20+00:00", "audio_release": "https://cdn.newsramp.net/audio/293fa383bc5a76e31f9db978e6ed4246.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/293fa383bc5a76e31f9db978e6ed4246.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-7.jpg", "site_handle": "newmediawire", "seo_description": "GeoVax Labs announces Phase 3 trial plans for GEO-MVA mpox/smallpox vaccine in 2026, addressing global supply constraints with accelerated regulatory pathway and manufacturing readiness.", "newsramp_curated": "https://newsramp.com/curated-news/geovax-advances-mpox-smallpox-vaccine-toward-phase-3-trial-in-2026/293fa383bc5a76e31f9db978e6ed4246"}, {"feed_item_id": 30951, "prhash_id": "c6583cafc4bf9f57db625ff3726185e3", "headline": "HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation", "content": "        <article>        <h1>HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-8.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>HeartBeam's public offering provides investment opportunity in a company advancing portable cardiac detection technology with FDA-cleared 12-lead ECG systems and AI capabilities.</li>            <li>HeartBeam is conducting a public offering to fund commercialization of its FDA-cleared 12-lead synthesized ECG system, patch development, and AI initiatives through Titan Partners.</li>            <li>HeartBeam's technology enables portable cardiac monitoring outside medical facilities, potentially improving early detection and access to care for heart conditions worldwide.</li>            <li>HeartBeam creates the first cable-free device that collects 3D ECG signals and synthesizes them into 12-lead ECGs, holding over 20 patents for this innovation.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it signals a major step in making advanced, portable cardiac monitoring widely accessible. Heart disease remains a leading cause of death globally, and traditional ECG systems often require clinical visits, delaying diagnosis. HeartBeam's technology could enable remote, real-time heart monitoring, allowing for earlier detection of conditions like arrhythmias or heart attacks. This could save lives by getting patients to treatment faster and reduce healthcare burdens through preventative care. The funding boost may accelerate the deployment of these innovations, directly impacting patients, healthcare providers, and investors in the growing digital health sector.</p>        <h2>Summary</h2>        <p><p>HeartBeam (NASDAQ: BEAT), a pioneering medical technology company focused on cardiac care innovation, has announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The final size and terms of this offering are subject to market conditions, with all securities to be offered by the company itself. The capital raised is intended to advance the commercialization of its groundbreaking FDA-cleared 12-lead synthesized ECG system, a core product that represents a significant leap in portable cardiac monitoring. Additionally, the net proceeds will fuel further development of its extended-wear patch and heart attack detection initiatives, enhance its artificial intelligence capabilities, and support general working capital and corporate purposes. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for this financial move, which is detailed in the full press release available on the InvestorBrandNetwork website.</p><p>The company is at the forefront of transforming cardiac health management with its proprietary technology. HeartBeam is creating the first-ever cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from three non-coplanar directions and synthesizing these signals into a comprehensive 12-lead ECG. This platform technology is designed for portable devices that can be used anywhere a patient is located, delivering actionable heart intelligence directly to physicians. The innovation allows healthcare providers to identify cardiac health trends and acute conditions outside traditional medical facilities, potentially directing patients to appropriate care more swiftly. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for its 12-lead ECG synthesis software in December 2025. With over 20 issued patents supporting its technology enablement, HeartBeam is positioned to redefine remote cardiac monitoring. For the latest news and updates relating to BEAT, investors and interested parties can visit the company's dedicated newsroom.</p><p>This strategic financial initiative underscores HeartBeam's commitment to scaling its innovative solutions in a competitive medtech landscape. The public offering represents a critical step in funding the next phase of growth, from enhancing AI-driven diagnostics to expanding the commercial reach of its FDA-cleared systems. As forward-looking statements in the release caution, the offering involves typical market risks and uncertainties, but the intended use of proceeds highlights a clear roadmap toward improving cardiac care accessibility. The original release on www.newmediawire.com provides complete context, while the InvestorBrandNetwork website hosts essential disclaimers applicable to all published content. By leveraging this capital infusion, HeartBeam aims to accelerate its mission of bringing hospital-grade cardiac monitoring into everyday settings, potentially impacting millions of patients at risk for heart-related events.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/c6583cafc4bf9f57db625ff3726185e3.30951.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/c6583cafc4bf9f57db625ff3726185e3.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/heartbeam-beat-launches-proposed-public-offering-to-support-commercialization-and-ai-initiatives-7086366/c6583cafc4bf9f57db625ff3726185e3'>HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation.</a></p></div>        </article>    ", "published": "2026-04-15T19:30:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/c6583cafc4bf9f57db625ff3726185e3.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/c6583cafc4bf9f57db625ff3726185e3.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-8.jpg", "site_handle": "newmediawire", "seo_description": "HeartBeam announces public stock offering to fund commercialization of its FDA-cleared 12-lead ECG system and AI-driven cardiac monitoring tech, enhancing remote heart care.", "newsramp_curated": "https://newsramp.com/curated-news/heartbeam-launches-public-offering-to-fuel-cardiac-tech-innovation/c6583cafc4bf9f57db625ff3726185e3"}, {"feed_item_id": 30946, "prhash_id": "952900c048c66725e4245b57287e8e0e", "headline": "Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse", "content": "        <article>        <h1>Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse</h1>        <img src='https://cdn.newsramp.app/noticias-newswire/newsimage/952900c048c66725e4245b57287e8e0e.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Pablo's Pack T1D provides families with a strategic advantage by offering practical resources and community support to better manage Type 1 diabetes challenges.</li>            <li>The initiative works by sharing daily management experiences, providing educational resources, and organizing participation in fundraising walks to support scientific research.</li>            <li>This family's advocacy creates a supportive community that reduces isolation and advances research toward a cure, making tomorrow better for those with Type 1 diabetes.</li>            <li>A Jacksonville family transformed their son's Type 1 diabetes diagnosis into Pablo's Pack T1D, an inspiring initiative that builds community and supports research through fundraising walks.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news highlights a critical model of patient and family-led advocacy that directly addresses the daily realities of managing a chronic condition like Type 1 diabetes. For the millions of individuals and families affected globally, stories like this demonstrate that a diagnosis does not have to be faced in isolation. The work of Pablo's Pack T1D provides tangible resources and emotional support, which are essential for navigating complex care routines and the associated psychological burden. Furthermore, their focus on driving participation in established fundraising events like the Breakthrough T1D Walk channels community energy directly toward accelerating research for better treatments and a potential cure. This grassroots-to-global approach empowers affected families, strengthens support networks, and directly contributes to the scientific and systemic advancements needed to ultimately reduce the disease's lifelong impact.</p>        <h2>Summary</h2>        <p><p>In Jacksonville, Florida, a family has transformed their personal experience with Type 1 diabetes into a powerful force for advocacy and community support through their initiative, Pablo\u2019s Pack T1D. When Andrea and her husband Pablo received the life-changing diagnosis that their son had Type 1 diabetes, they channeled their initial uncertainty into a shared mission. Their platform, accessible via Pablo\u2019s Pack T1D, serves as a vital resource hub, sharing the family's firsthand experiences with daily glucose monitoring, necessary lifestyle adjustments, and the emotional resilience required to manage this chronic condition. By providing these resources, they aim to foster a supportive community for other families navigating similar challenges, ensuring no one feels alone on this journey.</p><p>The family's advocacy extends beyond their digital platform through active participation in the Breakthrough T1D Walk, a national fundraising initiative. This event is a cornerstone of their efforts, bringing together families, advocates, and supporters to advance critical research and improve the lives of those living with Type 1 diabetes. As Andrea poignantly stated, their son's diagnosis 'gave us a purpose,' driving them to connect with others and work toward a better future. The walk supports efforts to accelerate scientific breakthroughs, improve access to care, and advance toward a cure, while also creating invaluable opportunities for peer connection and shared experience.</p><p>Through storytelling and community engagement, Pablo\u2019s Pack T1D continues to raise awareness and encourage participation in initiatives that support ongoing research and advocacy. It is important to note that Pablo\u2019s Pack T1D is a community-driven initiative, not a registered nonprofit; donations associated with their participation are directed to Breakthrough T1D, a registered 501(c)(3) organization funding research, advocacy, and education programs. This ensures contributions directly support the mission to improve lives and find a cure. Their story, detailed at their website, exemplifies how personal adversity can be harnessed to build community, provide practical support, and fuel the collective push for medical progress in the fight against Type 1 diabetes.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/952900c048c66725e4245b57287e8e0e.30946.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/952900c048c66725e4245b57287e8e0e.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.noticiasnewswire.com/'>Noticias Newswire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/noticias-newswire/en//952900c048c66725e4245b57287e8e0e'>Jacksonville Family Turns Son's T1D Diagnosis Into Advocacy Powerhouse.</a></p></div>        </article>    ", "published": "2026-04-15T17:34:36+00:00", "audio_release": "https://cdn.newsramp.net/audio/952900c048c66725e4245b57287e8e0e.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/952900c048c66725e4245b57287e8e0e.webp", "enclosure": "https://cdn.newsramp.app/noticias-newswire/newsimage/952900c048c66725e4245b57287e8e0e.jpg", "site_handle": "noticias-newswire", "seo_description": "A Jacksonville family transforms their son's Type 1 diabetes diagnosis into Pablo's Pack T1D, an advocacy initiative providing resources & driving support for the Breakthrough T1D Walk to fund research.", "newsramp_curated": "https://newsramp.com/curated-news/jacksonville-family-turns-son-s-t1d-diagnosis-into-advocacy-powerhouse/952900c048c66725e4245b57287e8e0e"}, {"feed_item_id": 30941, "prhash_id": "59a10dde8494de46441798c5e283d06d", "headline": "Earth Science Tech Builds Value Through Healthcare Acquisitions", "content": "        <article>        <h1>Earth Science Tech Builds Value Through Healthcare Acquisitions</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Earth Science Tech Builds Value Through Healthcare Acquisitions'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Earth Science Tech's strategic acquisitions in compounding pharmacies and telehealth platforms create a diversified healthcare portfolio that enhances shareholder value through scalable growth.</li>            <li>Earth Science Tech operates as a holding company that acquires and manages healthcare businesses, including compounding pharmacies and telehealth platforms, to optimize operations and drive long-term value.</li>            <li>Earth Science Tech's subsidiaries provide personalized wellness programs and prescription cost assistance through its nonprofit foundation, improving healthcare access for diverse communities across the United States.</li>            <li>Earth Science Tech's portfolio includes compounding pharmacies serving over 20 states and a telemedicine platform offering doctor-verified treatments through innovative healthcare delivery models.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it highlights Earth Science Tech's strategic expansion in the growing healthcare and telemedicine sectors, which have seen increased demand and innovation. For investors, the company's focus on capital discipline and long-term value creation across compounding pharmacies, telehealth platforms, and community health services presents a diversified approach to tapping into healthcare trends. The emphasis on personalized wellness programs and prescription cost assistance through its foundation also addresses broader societal needs for accessible healthcare. As healthcare continues to evolve with technology and personalized medicine, Earth Science Tech's portfolio could position it for sustainable growth, making it relevant for those monitoring investment opportunities in health-focused holding companies.</p>        <h2>Summary</h2>        <p><p>Earth Science Tech (OTC: ETST), a strategic holding company, has been featured in a recent article highlighting its disciplined approach to building value through acquisitions and active management of businesses. The company prioritizes capital discipline, execution, and long-term value creation across its diverse portfolio, focusing on scaling sustainable businesses to increase shareholder value. Key players include Earth Science Tech's leadership team and its network of subsidiaries, which form the core of its operational strategy.</p><p>The company's portfolio includes several healthcare-focused subsidiaries: Mister Meds LLC, a compounding pharmacy offering personalized wellness plans; RxCompoundStore.com LLC, another compounding pharmacy authorized in over 20 states and Puerto Rico; Peaks Curative LLC, a telemedicine referral platform; Las Villas Health Care Inc., serving Spanish-speaking communities with personalized wellness programs; DOConsultations LLC, a telehealth platform supporting direct delivery through partner pharmacies; and Earth Science Foundation Inc., the company's charitable arm providing prescription cost assistance. These operations demonstrate Earth Science Tech's commitment to the healthcare sector through compounding pharmaceuticals, telemedicine, and real estate development.</p><p>The article was published by NetworkNewsWire (NNW), a specialized communications platform within the Dynamic Brand Portfolio at IBN that provides financial news distribution and corporate communications solutions. NNW offers services including wire solutions via InvestorWire, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications. Readers can access the full article through the provided hyperlink and stay updated via the company's newsroom. This coverage reflects Earth Science Tech's efforts to gain recognition in the investment community while showcasing its multi-faceted approach to value creation in the competitive healthcare market.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/59a10dde8494de46441798c5e283d06d.30941.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/59a10dde8494de46441798c5e283d06d.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//59a10dde8494de46441798c5e283d06d'>Earth Science Tech Builds Value Through Healthcare Acquisitions.</a></p></div>        </article>    ", "published": "2026-04-15T16:53:55+00:00", "audio_release": "https://cdn.newsramp.net/audio/59a10dde8494de46441798c5e283d06d.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/59a10dde8494de46441798c5e283d06d.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-7.jpg", "site_handle": "ibn", "seo_description": "Earth Science Tech (ETST) featured for strategic healthcare acquisitions, including compounding pharmacies and telemedicine platforms. Learn about its value creation approach and subsidiaries like Mister Meds and RxCompoundStore.", "newsramp_curated": "https://newsramp.com/curated-news/earth-science-tech-builds-value-through-healthcare-acquisitions/59a10dde8494de46441798c5e283d06d"}, {"feed_item_id": 30935, "prhash_id": "f2b67e7087d6ddee76cb962a6ec4b200", "headline": "Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions", "content": "        <article>        <h1>Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Earth Science Tech's strategic acquisitions and capital discipline create a diversified healthcare portfolio that can deliver sustainable growth and increased shareholder value.</li>            <li>Earth Science Tech operates as a holding company managing subsidiaries in compounding pharmacies, telemedicine platforms, and healthcare services to optimize operations and build long-term value.</li>            <li>Through its subsidiaries and nonprofit foundation, Earth Science Tech provides personalized healthcare, telehealth access, and prescription cost assistance, improving wellness for diverse communities across the United States.</li>            <li>Earth Science Tech's portfolio includes compounding pharmacies serving over 20 states, Spanish-language healthcare services, and a charitable foundation helping with prescription costs.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it highlights Earth Science Tech's expansion in the growing telehealth and personalized medicine sectors, which are increasingly important as healthcare shifts toward remote and customized solutions. For investors, the company's disciplined acquisition strategy and diversified portfolio\u2014spanning compounding pharmacies, telemedicine platforms, and even real estate\u2014suggest potential for sustainable growth and value creation. For consumers, especially those in underserved communities like Spanish-speaking populations, the company's services offer improved access to personalized wellness plans and prescription assistance. The involvement of platforms like InvestorWire ensures broader market awareness, which could influence investment decisions and industry trends in healthcare innovation.</p>        <h2>Summary</h2>        <p><p>Earth Science Tech (OTC: ETST), a strategic holding company, has been featured in a recent article highlighting its disciplined approach to building value through acquisitions and active management of healthcare businesses. The company emphasizes capital discipline, execution, and long-term value creation across its diverse portfolio, which includes multiple subsidiaries focused on compounding pharmaceuticals, telemedicine, and personalized wellness. Key players in this ecosystem include Mister Meds LLC, a compounding pharmacy delivering personalized wellness plans across the USA; RxCompoundStore.com LLC, another compounding pharmacy authorized in over 20 states and Puerto Rico; Peaks Curative LLC, a telemedicine referral platform; Las Villas Health Care Inc., serving Spanish-speaking communities; DOConsultations LLC, a telehealth platform; and Earth Science Foundation Inc., the company's charitable arm providing prescription cost assistance.</p><p>The article, available through the InvestorWire platform, details how Earth Science Tech operates as a strategic holding company focused on operational optimization and management of its wholly owned and majority-owned subsidiaries. Beyond the healthcare-focused entities, the company also maintains interests in real estate development through Avenvi, LLC and an 80% stake in MagneChef, demonstrating a diversified approach to value creation. The coverage was distributed via InvestorWire, which is part of the Dynamic Brand Portfolio at IBN, leveraging advanced wire-grade press release syndication, editorial distribution to over 5,000 outlets, and enhanced social media distribution to reach investors and the general public effectively.</p><p>For investors seeking the latest updates, the company maintains a dedicated newsroom accessible through the provided link. This comprehensive approach to corporate communications ensures that Earth Science Tech's strategic initiatives in compounding pharmaceuticals, telemedicine, and beyond receive appropriate market visibility. The company's focus on scaling sustainable businesses that increase shareholder value while addressing specific healthcare needs\u2014from personalized wellness plans to financial assistance for prescriptions\u2014positions it uniquely in the evolving healthcare landscape.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/f2b67e7087d6ddee76cb962a6ec4b200.30935.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/f2b67e7087d6ddee76cb962a6ec4b200.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//f2b67e7087d6ddee76cb962a6ec4b200'>Earth Science Tech Builds Healthcare Empire Through Strategic Acquisitions.</a></p></div>        </article>    ", "published": "2026-04-15T16:26:27+00:00", "audio_release": "https://cdn.newsramp.net/audio/f2b67e7087d6ddee76cb962a6ec4b200.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/f2b67e7087d6ddee76cb962a6ec4b200.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-4.jpg", "site_handle": "ibn", "seo_description": "Earth Science Tech (ETST) expands its healthcare portfolio with strategic acquisitions in compounding pharmacies and telemedicine, focusing on personalized wellness and shareholder value creation.", "newsramp_curated": "https://newsramp.com/curated-news/earth-science-tech-builds-healthcare-empire-through-strategic-acquisitions/f2b67e7087d6ddee76cb962a6ec4b200"}, {"feed_item_id": 30933, "prhash_id": "69291ab3509dbbeb4769519576a4aa18", "headline": "Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation", "content": "        <article>        <h1>Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation</h1>        <img src='https://cdn.newsramp.app/banners/awards-6.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Kairos Pharma's Emerald award recognition at the 2026 Pinnacle Awards signals a competitive edge in developing resistance-modulating cancer treatments that could enhance therapy effectiveness.</li>            <li>Kairos Pharma's ENV-105 targets the CD105 protein to inhibit tumor resistance pathways, using structural biology to restore standard therapy effectiveness in clinical trials for multiple cancers.</li>            <li>Kairos Pharma's innovative approach to overcoming cancer drug resistance aims to improve patient outcomes and durability of response, making tomorrow better for those battling the disease.</li>            <li>Kairos Pharma's lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of cancer relapse and resistance to standard therapies.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because cancer drug resistance remains one of the most significant challenges in oncology, often leading to treatment failure and disease progression. When cancer cells develop resistance to standard therapies, patients face limited options and poorer outcomes. Kairos Pharma's approach to modulating resistance pathways represents a promising direction in cancer treatment that could extend the effectiveness of existing therapies and improve patient survival rates. The company's focus on combination approaches addresses a critical need in cancer care, potentially benefiting millions of patients worldwide who face treatment-resistant cancers. The recognition at the prestigious Pinnacle Awards validates the scientific merit of this approach and signals progress toward more durable cancer treatments.</p>        <h2>Summary</h2>        <p><p>Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has been honored as an Emerald honoree at the prestigious 2026 Pinnacle Awards for Healthcare. This recognition celebrates the company's innovative strategy to combat cancer drug resistance, a major challenge in oncology treatment. The company's approach focuses on resistance-modulating treatments, with its lead candidate ENV-105 (carotuximab) designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies. Kairos Pharma is advancing combination approaches aimed at improving durability of response across multiple cancer indications, positioning itself at the forefront of oncology therapeutics.</p><p>Based in Los Angeles, California, Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105\u2014a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. It's important to note that as of the press release date, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.</p><p>The press release was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides advanced wire-grade press release syndication for private and public companies and the investment community, offering access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement for maximum impact, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information about Kairos Pharma, investors can visit the company's newsroom at https://ibn.fm/KAPA or view the full press release at https://ibn.fm/ghPJC.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/69291ab3509dbbeb4769519576a4aa18.30933.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/69291ab3509dbbeb4769519576a4aa18.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//69291ab3509dbbeb4769519576a4aa18'>Kairos Pharma Wins 2026 Pinnacle Award for Cancer Drug Resistance Innovation.</a></p></div>        </article>    ", "published": "2026-04-15T15:59:35+00:00", "audio_release": "https://cdn.newsramp.net/audio/69291ab3509dbbeb4769519576a4aa18.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/69291ab3509dbbeb4769519576a4aa18.webp", "enclosure": "https://cdn.newsramp.app/banners/awards-6.jpg", "site_handle": "ibn", "seo_description": "Kairos Pharma wins 2026 Pinnacle Award for innovative cancer drug resistance treatments. Learn about ENV-105 clinical trials and their approach to overcoming treatment resistance in oncology.", "newsramp_curated": "https://newsramp.com/curated-news/kairos-pharma-wins-2026-pinnacle-award-for-cancer-drug-resistance-innovation/69291ab3509dbbeb4769519576a4aa18"}, {"feed_item_id": 30927, "prhash_id": "d794b4f99420806b0bb7ba29bb744d38", "headline": "Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation", "content": "        <article>        <h1>Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-3.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Polyrizon secured $3.5 million in funding, providing capital to advance its intranasal protective technology and potentially gain an edge in biotech innovation.</li>            <li>Polyrizon raised $3.5 million through a direct offering and private placement, selling units at $9.00 each to fund working capital and corporate operations.</li>            <li>Polyrizon's nasal spray technology creates a protective barrier against viruses and allergens, aiming to improve public health and reduce disease transmission.</li>            <li>Polyrizon is developing a nasal hydrogel that acts as a biological mask, using natural building blocks to trap viruses before they infect tissue.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because Polyrizon's intranasal protective technology represents a potentially transformative approach to respiratory health protection. In a world increasingly concerned about viral transmission and airborne allergens, a non-invasive nasal barrier could offer significant advantages over traditional masks and medications. The funding enables continued research and development of what essentially functions as a 'biological mask' - technology that could provide continuous protection without the discomfort and limitations of physical face coverings. For investors, this represents an opportunity in the growing biotech sector focused on preventive healthcare solutions. For the general public, successful development could lead to more convenient, effective protection against respiratory illnesses and allergens, potentially reducing healthcare costs and improving quality of life for millions who suffer from seasonal allergies or are at risk of viral infections. The company's additional work on drug delivery through nasal sprays could also revolutionize how medications are administered, making treatments more targeted and efficient.</p>        <h2>Summary</h2>        <p><p>Polyrizon Ltd. (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company, has successfully secured approximately $3.5 million in gross proceeds through a registered direct offering and concurrent private placement with a single institutional investor. The financial transactions involved the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, which included ordinary shares or pre-funded warrants and common warrants, with additional warrants issued in the private placement. Aegis Capital Corp. served as the exclusive placement agent for these deals, and the company intends to allocate the proceeds toward working capital and general corporate purposes, bolstering its operational capabilities during this critical development phase.</p><p>At the core of Polyrizon's innovative approach is its proprietary Capture and Contain\u2122 (C&C) hydrogel technology, which forms the basis of its intranasal protective solutions. This technology, delivered via nasal sprays, creates a thin hydrogel-based shield containment barrier in the nasal cavity, designed to act as a 'biological mask' by preventing viruses and allergens from contacting nasal epithelial tissue. The company is further advancing its C&C hydrogel technology to enhance bioadhesion and prolonged retention for intranasal drug delivery, while also developing an earlier-stage pre-clinical technology called Trap and Target\u2122 (T&T) focused on nasal delivery of active pharmaceutical ingredients (APIs). For more detailed information, readers can view the full press release through the provided link.</p><p>The news was disseminated by TechMediaWire (TMW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on technology-driven companies. TMW provides comprehensive services including access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media distribution through IBN's network, and tailored corporate communications solutions. This platform helps companies like Polyrizon reach a wide audience of investors, influencers, consumers, and journalists, ensuring maximum visibility in today's crowded information landscape. For those interested in staying updated on technology news, TMW offers SMS alerts by texting 'TECH' to 888-902-4192 (U.S. Mobile Phones Only).</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/d794b4f99420806b0bb7ba29bb744d38.30927.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/d794b4f99420806b0bb7ba29bb744d38.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//d794b4f99420806b0bb7ba29bb744d38'>Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation.</a></p></div>        </article>    ", "published": "2026-04-15T14:48:22+00:00", "audio_release": "https://cdn.newsramp.net/audio/d794b4f99420806b0bb7ba29bb744d38.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/d794b4f99420806b0bb7ba29bb744d38.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-3.jpg", "site_handle": "ibn", "seo_description": "Polyrizon raises $3.5M for nasal hydrogel technology that creates a biological mask barrier against viruses and allergens. Learn about their innovative Capture and Contain\u2122 platform.", "newsramp_curated": "https://newsramp.com/curated-news/polyrizon-secures-3-5m-funding-for-nasal-shield-biotech-innovation/d794b4f99420806b0bb7ba29bb744d38"}, {"feed_item_id": 30925, "prhash_id": "b53c1abe1d870e97785c31aec2c6960a", "headline": "Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors", "content": "        <article>        <h1>Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors</h1>        <img src='https://cdn.newsramp.app/banners/science-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>CNS Pharmaceuticals Inc. gains a competitive edge by targeting newly discovered glioblastoma-supporting cells, potentially accelerating effective treatment development.</li>            <li>Canadian scientists found that passive brain cells actively fuel glioblastoma growth through signaling, revealing a new therapeutic target for companies like CNS Pharmaceuticals Inc.</li>            <li>This discovery offers hope for better glioblastoma treatments, potentially improving survival rates and quality of life for patients worldwide.</li>            <li>Brain cells once thought passive secretly fuel deadly cancer growth, a surprising finding that could revolutionize glioblastoma treatment approaches.</li>        </ul>        <h2>Why it Matters</h2>        <p>This discovery fundamentally changes our understanding of glioblastoma biology by revealing that non-cancerous brain cells actively contribute to tumor growth rather than just providing passive support. For patients facing this aggressive brain cancer with limited treatment options, this finding opens new therapeutic avenues that could target these supportive cells alongside cancer cells themselves. The research could lead to more effective combination therapies and potentially improve survival rates for a disease that currently has a devastating prognosis. For investors and the medical community, it highlights the importance of continued research investment and the potential for companies like CNS Pharmaceuticals to develop novel treatments based on these biological insights.</p>        <h2>Summary</h2>        <p><p>Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer, revealing that cells previously considered passive support structures in healthy brain tissue actually actively fuel tumor growth through signaling that boosts cancer cell function. This discovery challenges long-held assumptions about brain cancer biology and opens new avenues for therapeutic intervention against a disease notorious for its aggressive nature and limited treatment options.</p><p>The rush to develop effective therapies against glioblastoma is gaining momentum, with entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) working tirelessly to bring to market new treatments that move the dial in the fight against this deadly type of brain cancer. As more insights about what drives tumor progression emerge, companies like CNS Pharmaceuticals are positioned to translate these scientific breakthroughs into clinical applications, potentially offering hope where traditional approaches have fallen short.</p><p>This news is presented by TinyGems, a specialized communications platform within the Dynamic Brand Portfolio at IBN that focuses on innovative small-cap and mid-cap companies with bright futures and huge potential. Through services like article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of followers, TinyGems helps companies reach a wide audience of investors, influencers, and the general public. The platform's comprehensive corporate communications solutions ensure that important developments in fields like oncology research receive the visibility they deserve, connecting scientific progress with investment opportunities and public awareness.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/b53c1abe1d870e97785c31aec2c6960a.30925.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/b53c1abe1d870e97785c31aec2c6960a.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//b53c1abe1d870e97785c31aec2c6960a'>Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors.</a></p></div>        </article>    ", "published": "2026-04-15T14:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/b53c1abe1d870e97785c31aec2c6960a.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/b53c1abe1d870e97785c31aec2c6960a.webp", "enclosure": "https://cdn.newsramp.app/banners/science-7.jpg", "site_handle": "ibn", "seo_description": "Canadian scientists discover brain cells actively fuel glioblastoma growth, challenging cancer biology. CNS Pharmaceuticals develops new treatments as TinyGems reports on this breakthrough finding.", "newsramp_curated": "https://newsramp.com/curated-news/canadian-scientists-discover-brain-cells-fuel-deadly-glioblastoma-tumors/b53c1abe1d870e97785c31aec2c6960a"}, {"feed_item_id": 30922, "prhash_id": "768e527ea006665133e893e3058a5306", "headline": "Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment", "content": "        <article>        <h1>Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment</h1>        <img src='https://cdn.newsramp.app/banners/technology-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Tonix Pharmaceuticals' TONMYA offers faster absorption and higher bioavailability than existing treatments, potentially capturing market share in fibromyalgia care.</li>            <li>A peer-reviewed study of 60 volunteers shows TNX-102 SL achieves faster absorption and higher bioavailability than oral cyclobenzaprine for bedtime dosing.</li>            <li>This new formulation could improve sleep and reduce pain for fibromyalgia patients, enhancing daily functioning and quality of life.</li>            <li>Tonix's sublingual tablet is the first new fibromyalgia treatment in 15 years, using faster absorption to target nonrestorative sleep.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because fibromyalgia affects millions worldwide, often causing chronic pain, fatigue, and sleep disturbances that significantly impair quality of life. The condition has seen limited treatment advances in recent years, leaving many patients with inadequate options. TONMYA's sublingual formulation offering faster absorption and improved bioavailability could provide more effective symptom management, particularly for nonrestorative sleep\u2014a core fibromyalgia complaint. Beyond immediate patient benefits, Tonix's broader pipeline targeting CNS disorders and immunological conditions addresses multiple areas of high unmet medical need. The company's research into TONMYA for depression and stress disorders, along with programs for rare diseases like Prader-Willi syndrome and transplant rejection prevention, demonstrates a comprehensive approach to challenging medical conditions. For investors and the healthcare community, Tonix represents innovation in biotechnology with potential market impact across several therapeutic areas.</p>        <h2>Summary</h2>        <p><p>Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a commercial-stage biotechnology company, has announced a significant milestone with the publication of a peer-reviewed study in <em>Clinical Pharmacology in Drug Development</em>. The research details the steady-state pharmacokinetic properties of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(R). Conducted with 60 healthy volunteers, the study demonstrated that this sublingual formulation achieves faster absorption, earlier peak plasma concentration, and higher dose-normalized bioavailability compared to oral extended-release cyclobenzaprine. These findings support TONMYA's use for long-term bedtime dosing to target nonrestorative sleep in fibromyalgia patients, potentially reducing pain and improving related symptoms. This development is particularly noteworthy as TONMYA represents the first new treatment for fibromyalgia in over 15 years, addressing a condition with high unmet medical need.</p><p>Tonix Pharmaceuticals is a fully-integrated company focused on central nervous system (CNS) and immunology treatments. Beyond TONMYA, their commercial infrastructure supports marketed acute migraine products including Zembrace(R) SymTouch(R) and Tosymra(R). The company is actively exploring TONMYA's potential in other areas through Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, Tonix's pipeline includes TNX-2900, which is Phase 2 ready for treating Prader-Willi syndrome, and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. It's important to note that while promising, these product development candidates remain investigational new drugs or biologics whose efficacy and safety have not been established for any indication.</p><p>This news was disseminated through TinyGems, a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on innovative small-cap and mid-cap companies. TinyGems provides comprehensive corporate communications solutions including access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution through IBN's extensive network. The platform aims to deliver unparalleled recognition and brand awareness for companies seeking to reach investors, influencers, consumers, and journalists. For those interested in following developments from companies like Tonix Pharmaceuticals, TinyGems offers SMS alerts by texting 'Gems' to 888-902-4192 (U.S. mobile phones only). Additional information and disclaimers are available on the TinyGems website.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/768e527ea006665133e893e3058a5306.30922.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/768e527ea006665133e893e3058a5306.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//768e527ea006665133e893e3058a5306'>Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment.</a></p></div>        </article>    ", "published": "2026-04-15T14:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/768e527ea006665133e893e3058a5306.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/768e527ea006665133e893e3058a5306.webp", "enclosure": "https://cdn.newsramp.app/banners/technology-4.jpg", "site_handle": "ibn", "seo_description": "Tonix Pharmaceuticals publishes study showing TONMYA's faster absorption for fibromyalgia treatment. First new fibromyalgia drug in 15 years with potential for improved sleep and pain management.", "newsramp_curated": "https://newsramp.com/curated-news/tonix-pharma-s-tonmya-study-shows-faster-absorption-for-fibromyalgia-treatment/768e527ea006665133e893e3058a5306"}]}